Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates.

ABSTRACT: Chimeric antigen receptor (CAR) T cells targeting CD19+ hematologic malignancies have rapidly emerged as a promising, novel therapy. In contrast, results from the few CAR T-cell studies for infectious diseases such as HIV-1 have been less convincing. These challenges are likely due to the low level of antigen present in antiretroviral therapy (ART)-suppressed patients in contrast to those with hematologic malignancies. Using our well-established nonhuman primate model of ART-suppressed HIV-1 infection, we tested strategies to overcome these limitations and challenges. We first optimized CAR T-cell production to maintain central memory subsets, consistent with current clinical paradigms. We hypothesized that additional exogenous antigen might be required in an ART-suppressed setting to aid

SUBMITTER: Rust BJ 

PROVIDER: S-EPMC7544543 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature